Extract
Cytogen Reports Third Quarter 2007 Financial Results.
PRINCETON, N.J. -- Cytogen Corporation (NASDAQ: CYTO) today reported its financial results for the third quarter of 2007.
Revenues for the third quarter of 2007 increased to $5.1 million compared to $4.2 million for the same period in 2006 due to an increase in QUADRAMET[R] (samarium Sm-153 lexidronam injection) sales and the recognition of CAPHOSOL[R] (supersaturated calcium phosphate rinse) sales. Cytogen introduced CAPHOSOL to the U.S. oncology market in March 2007. CAPHOSOL is a treatment for both oral mucositis and dry mouth, two significant complications of a number of common ca...See the full content of this document
Sponsored links
